Physician profile
Gary Vanetsky
NPI 1417034489
$22,759.18
in general payments reported to CMS, 2019-2025
36 companies · $5,880 in 2025
The $5,880 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,980 · 2022: $3,430 · 2023: $5,680 · 2024: $5,789 · 2025: $5,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,302 · Honoraria: $1,200 · Education: $396 · Travel and Lodging: $31.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,418.68 |
| Consulting Fee | $1,302.00 |
| Honoraria | $1,200.00 |
| Education | $396.03 |
| Travel and Lodging | $31.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,978.69 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,490.08 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $2,085.41 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $1,743.13 | 2021-2025 | Tremfya |
| Pfizer INC. | $1,423.40 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,391.42 | 2021-2025 | Ilumya, Winlevi |
| Lnhc, INC | $1,200.00 | 2025 | Zelsuvmi |
| Ucb, INC. | $1,096.10 | 2021-2025 | Bimzelx |
| Epi Health, LLC | $1,061.15 | 2021-2022 | |
| Lilly USA, LLC | $966.27 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $857.92 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $787.53 | 2022-2025 | |
| Dermavant Sciences, INC. | $685.97 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $630.60 | 2021-2025 | Tremfya |
| Incyte Corporation | $580.78 | 2022-2025 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $522.03 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $497.16 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $450.85 | 2021-2025 | Libtayo, Dupixent |
| Journey Medical Corporation | $197.17 | 2022-2025 | |
| Organon LLC | $184.14 | 2025 | Vtama |
| Almirall LLC | $141.47 | 2021-2025 | Klisyri |
| Verrica Pharmaceuticals INC. | $112.50 | 2023-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.36 | 2021-2023 | Arazlo, Jublia |
| Vyne Pharmaceuticals INC. | $90.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $71.72 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $60.54 | 2021 | |
| Biofrontera INC. | $55.57 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.08 | 2023-2025 | Spevigo |
| Dermira, INC. | $49.67 | 2021 | |
| Genentech USA, INC. | $44.18 | 2021-2022 | |
| Organogenesis INC. | $36.40 | 2024 | |
| Strata Skin Sciences, INC. | $34.66 | 2021 | |
| Paratek Pharmaceuticals, INC. | $29.58 | 2025 | Nuzyra |
| Botanix Sb INC | $21.49 | 2025 | Sofdra |
| Tempus Ai, INC | $16.35 | 2024 | Merlin Test |
| Bioventus LLC | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Vanetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.